Researchers at the Icahn School of Medicine at Mount Sinai reported preclinical data showing IL‑12–producing CAR T cells targeted to tumor‑associated macrophages (TAMs) reprogram the tumor microenvironment and improved survival in aggressive mouse models of metastatic ovarian and lung cancer. The approach emphasizes targeting suppressive myeloid cells rather than tumor antigens alone. The team published results in Cancer Cell demonstrating that armored CAR T cells depleted immunosuppressive TAMs, induced local immune activation and enabled anti‑tumor responses in models that are refractory to other immunotherapies. Authors and institutional leaders described the strategy as a potential new route to treat solid tumors by opening immune access to tumor cells.